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63 
ABSTRACT 64 
Introduction 65 
Following the major outbreak of pertussis and 14 infant deaths across England  in 2012,  66 
the Department of Health (DH) introduced the UK’s first maternal pertussis vaccination 67 
programme.  Data published by Public Health England (PHE) suggest uptake of the 68 
vaccine varies considerably across the country. The reasons for this heterogeneity need 69 
to be addressed to optimise the impact of the program. 70 
Objective 71 
To assess uptake of antenatal pertussis and influenza vaccine in a leading NHS Trust in 72 
London and to explore awareness and attitudes of pregnant women towards the pertussis 73 
vaccination programme. 74 
Design 75 
A cross sectional survey was conducted in an ethnically diverse group of 200 pregnant 76 
women accessing antenatal care at Imperial Healthcare NHS Trust. Quantitative data was 77 
tabulated and content analysis was carried out on the free text. Qualitative data was 78 
divided into themes for accepting or declining  the vaccine.  79 
Results 80 
Awareness of the program was 63% (126/200) with actual uptake of the vaccine only 81 
26.0% (52/200).  Women had received information from multiple sources, primarily 82 
General Practitioners (GP) and midwives. 34.0% (68/200) of women were offered the 83 
vaccine at their GP practice, but only 24% reported a meaningful discussion with their GP 84 
about it. Uptake  differed by up to 15.0% between ethnicities. Qualitative data showed 85 
that uptake could be significantly enhanced if vaccination was recommended by a familiar 86 
healthcare professional. Feeling uninformed, lack of professional encouragement and 87 
uncertainties of risk and benefit of the vaccine were the greatest barriers to uptake. 88 
Conclusion  89 
Vaccine uptake in this cohort of pregnant women was poor. Understanding the target 90 
audience and engaging with key groups who influence women’s decision-making is 91 
essential. Knowledgeable health care professionals need to recommend the vaccine and 92 
provide accurate and timely information to increase success of this important program. 93 
 94 
 95 
 96 
1. INTRODUCTION 97 
Pertussis (whooping cough) is a highly contagious, acute bacterial infection of the 98 
respiratory tract caused by Bordetella pertussis. This exclusively human pathogen can 99 
affect people of all ages. Whilst adolescents and adults often display relatively mild  100 
symptoms, in unimmunised newborn infants the disease may run a severe course 101 
resulting in a high rate of complications and death, [1,2]. Pertussis persists as an infection 102 
of significant global public health importance leading to 126,000 deaths worldwide in 103 
children up to the age of 5 years in 2013,[3].  104 
Fortunately, wide-scale childhood vaccination programmes have been influential in 105 
reducing the morbidity and mortality associated with pertussis,[4, 5, 6, 7].  However, 106 
despite high vaccine coverage, a sharp increase in cases has been observed over the 107 
past decade,[8,9,10,11] in several countries in Europe, North America and Australia, most 108 
likely due to waning immunity after the introduction of the acellular pertussis vaccine,[12]. 109 
In the UK, pertussis currently remains the most common cause of hospitalisation and 110 
deaths in infants from a vaccine-preventable disease,[5,13].  111 
In late 2011 the UK witnessed a remarkable resurgence of confirmed pertussis cases to a 112 
level not seen for almost 20 years. By 2012, infected cases had risen tenfold and the 113 
outbreak was extending to infants too young to be protected through routine vaccination. 114 
Sadly, a total of 14 infant deaths were reported in England in that year. Consequently, an 115 
urgent review by the UK Joint Committee on Vaccination and Immunisation (JCVI) 116 
recommended to the Department of Health (DH) that pregnant women should be offered 117 
routine vaccination with a five component acellular-pertussis containing vaccine, and this 118 
program was initiated in October 2012, and was offered to all pregnant women between 119 
28 and 38 weeks of pregnancy within the UK National Health Service (NHS)[14] 120 
A subsequent Public Health communications campaign to inform women about the need 121 
for vaccination and to stimulate uptake ran for approximately 5 months, including 122 
publication of a range of printed materials, available on order. Communication with 123 
healthcare professionals used DH and NHS channels and relied upon Heads of 124 
Profession to convey key messages and clinical information about pertussis. The Primary 125 
Care Trusts (PCTs) were asked to establish vaccination services quickly using local GP 126 
Practices,[15]. Vaccine stocks were delivered to GP practices and the hospital pharmacy 127 
held only a limited stock of vaccine for women who were long-term antenatal inpatients. 128 
The intervention aims to minimise morbidity and prevent further infant deaths by boosting 129 
pre-existing maternal immunity and protect newborns indirectly via transplacentally 130 
transferred protective antibody, prior to receiving their own vaccines within the infant 131 
immunisation schedule,. During the summer of 2014 the upper gestation recommended 132 
for receiving the vaccine was reduced to 32 weeks, in light of recent evidence, [16] to 133 
ensure sufficient antibody transfer from mother to baby prior to birth. 134 
Despite measures taken to promote pertussis vaccination, monthly figures published by 135 
Public Health England (PHE) since the start of the campaign have revealed varied 136 
vaccine uptake across England with London achieving 53.3% coverage at best in 137 
February 2013,[17]. 138 
In 2013 and 2014, a further 10 deaths in infants occurred with nine of these infants born 139 
to non-vaccinated mothers. In light of these data and the recent announcement that the 140 
vaccination programme will continue for a further five years, [18], evaluation of the current 141 
pertussis vaccination programme in pregnancy is, therefore, timely and essential to inform 142 
the long-term strategy for optimising pertussis control.   143 
We undertook a cross sectional survey to evaluate women’s awareness, attitudes 144 
towards and acceptance of the current pertussis vaccination programme in order to 145 
identify potential barriers that could be addressed in order to improve implementation. 146 
2. MATERIALS AND METHODS 147 
2.1 Study design 148 
This study adopted  qualitative and quantitative research techniques in the form of a 149 
cross-sectional questionnaire survey. Self–reported qualitative information on attitudes to 150 
vaccines  and experiences was gained from the analysis of the free text. 151 
2.2 Ethical considerations 152 
 Ethical approval was granted by the London-Hampstead Research Ethics Committee 153 
reference:13/LO/1712. 154 
2.3 Theoretical framework and questionnaire development 155 
A four part, anonymised questionnaire was developed based upon  the Precaution 156 
Adoption Process Model and the Health Belief Model of health behavior [19,20,21]. 157 
Consideration was given to the potential for inaccuracy in self-reported vaccination 158 
status,[22,23,24] and questions were phrased in order to highlight any discrepancy and 159 
allow further questions to be asked. 160 
A pilot survey was conducted with six pregnant women from the target population to 161 
optimise the questionnaire to ensure that the ‘instrument’ was logical and comprehensive 162 
for the domain that it was intended to measure. A convenience  sampling strategy was 163 
adopted.  164 
2.4 Study population 165 
The questionnaire was administered to an ethnically diverse sample of pregnant women 166 
who were over 18 years old, at least 27 weeks pregnant and attending for routine 167 
pregnancy care over a one year period from May 2013 to June 2014.  168 
When approached by the Research Midwife in the antenatal clinic waiting area,each 169 
woman was given a full explanation of the survey, supported by an information leaflet and 170 
sufficient time to ask questions before making an informed decision to participate. All 171 
questionnaires were returned to the Research Midwife in a sealed envelope prior to 172 
leaving the clinic.  173 
2.5 Data analysis 174 
Questionnaires were collated and data was entered into an Access database, double-175 
checked for accuracy and subsequently exported into Microsoft Excel. Descriptive 176 
statistics such as percentages and means were calculated. Content analysis was applied 177 
to the free text and used to summarise recurring patterns across respondents. Quotes 178 
from the questionnaires were tabulated and repeated words and phrases were highlighted 179 
according to categories. Themes were derived from these to discern factors influencing 180 
women’s decisions to accept or decline vaccine, [25]. 181 
 182 
3. RESULTS 183 
205 questionnaires were distributed to eligible women. Five questionnaires were excluded 184 
due to insufficient response to multiple questions. 200 were completed and analysed 185 
(97.0% response rate).  186 
3.1 Respondent characteristics 187 
The average age of the respondents was 31.4 years (median, 31: range 18 – 34), the 188 
average gestation was 32 weeks (range 27 – 41weeks) and 46.0% (93) of the 189 
respondents were nulliparous. The respondents were of diverse ethnicities. Demographic 190 
details are summarised in Table 1. 191 
To assess cohort representativeness, the demographic data of the respondents was 192 
compared with key data extracted from the Ciconia Maternity Information System (CMIS) 193 
of all women booking for routine care at the same NHS antenatal clinic. This comparison 194 
showed no significant differences between the groups and was representative of the 195 
pregnant population attending the hospital Trust. 196 
 197 
 198 
 199 
Table 1. Characteristics of pregnant women participating in survey  200 
Characteristic Survey 
participants 
N=200 
 CMIS data 
comparison 
N=5877 
Average age (years) 
Range:  
31.4years 
18-43years 
 31.57years 
16-52years 
Parity (P) 
0                                                                           
≥1 
 
Parity range:  
 
     93(46.5%) 
   107(53.5%) 
 
P0 – P8 
  
 
  
Average gestation 
Range: 
 
32 weeks 
27- 41weeks 
  
Ethnicity 
Asian (British, Bangladeshi, Indian, Pakistani including  Chinese) 
Black (British, African, Caribbean) 
White (British, various other nationalities) 
Mixed 
Other ethnicities 
Did not want to say or not stated 
 
40 (20.0%) 
37 (18.5%) 
88 (44.0%) 
9 (4.5%) 
19 (9.5%) 
7 (3.5%) 
  
14% 
18% 
48.5% 
3.3% 
15.4% 
London postcodes 
NW2 
W2 
NW6 
NW10 
 
26 (13%) 
22 (11%) 
     21 (10.5%) 
19 (9.5%)  
  
 458 (7.8%) 
  602 (10.2%) 
520 (8.8%) 
  822 (13.9%) 
 201 
3.2 Uptake of pertussis vaccine 202 
Of the 200  respondents, 26.0% (52/200) had been vaccinated during their current 203 
pregnancy. 72.0% (144/200) had not received the vaccine and four women (2.0%) could 204 
not remember. Of the 144 women who had not been vaccinated, 79 (54.8%) stated that 205 
they were undecided about accepting the vaccine during this pregnancy but may consider 206 
it in the future (Fig.1). 207 
Uptake differed by ethnicity with the highest uptake amongst ‘White women’ with 29.5% 208 
(26/88) vaccinated. Within this group the highest uptake was  in the  “White – Other” 209 
ethnic group (predominantly Polish) with 36.0% (18/50) vaccinated. The lowest uptake of 210 
18.9% (7/37) was in the “Black/Black British  group with the poorest uptake being 7.1% 211 
(1/14) in Black Caribbean women.  Women who did not state their ethnicity had an uptake 212 
of 14.3% (1/7).  213 
3.3 Reasons for accepting pertussis vaccine 214 
Vaccinated women were asked to describe their reasons for accepting the pertussis 215 
vaccination with four themes emerging. 216 
 217 
3.3.1  The importance of encouragement and understanding 218 
The predominant reason given by 78.8% (41/52) of  women for accepting the vaccine was 219 
encouragement or recommendation by a healthcare professional known to them.  220 
When asked about their knowledge and understanding of the pertussis vaccine only 16 of 221 
the 52 vaccinated women could name the vaccine they had received or provide any detail 222 
in their response. This suggested that while women had opted to take the vaccine 223 
perhaps the information given was difficult to interpret or the discussion around this 224 
process had been limited. 225 
3.3.2  Keeping me and my baby safe  226 
Women believed that by receiving the vaccine they were acting in the best interests of 227 
their unborn baby by protecting themselves and reducing the risk of their baby developing 228 
pertussis in the early weeks following birth. 229 
3.3.3  Risk avoidance and precaution 230 
Other reasons given for accepting the vaccine included preventing the disease and 231 
preventing any damage caused to the baby as a result of pertussis infection. 232 
3.3.4  How experience influenced decision-making 233 
Identifying with the disease by knowing someone who had experienced pertussis, 234 
influenced women’s decisions to accept the vaccine. Personal experience of vaccine–235 
preventable illness also had a positive influence on decision-making.  236 
3.4 Impact of complications in pregnancy on decision making 237 
Forty three of the 200 respondents (21.5%) reported complications in their current 238 
pregnancy with 13 (6.5%) reporting gestational diabetes and 7 (3.5%) with pre-eclampsia. 239 
Of these women, 30.2% had received the pertussis vaccine. In contrast, only 22.9% of 240 
the 157 women with uncomplicated pregnancies had been vaccinated. 241 
3.5 Attitudes to vaccination in future pregnancies 242 
47.5% (95/200) of all the respondents expressed a willingness to accept the pertussis 243 
vaccine in their next pregnancy. Over one third (38.5%) were undecided, but only 8.0% 244 
stated they would not wish to take up the vaccine and 6% did not answer this question. 245 
3.6 Reasons for declining pertussis vaccine 246 
Unvaccinated women were asked to describe their reasons for declining the pertussis 247 
vaccination during pregnancy and gave a number of different reasons for declining the 248 
pertussis vaccine, as summarised in Table 2. Five women gave more than one reason.  249 
 250 
 251 
 252 
Table 2. Reasons for declining vaccine 253 
Question: If you have decided not to have the whooping cough 
vaccination, why did you take this decision? 
N=144  
 
Not aware and never informed about the vaccine 
Insufficient information about the vaccine 
Safety concerns as we need more research evidence to show 
efficacy/safety 
Trust in natural immunity and lifestyle 
Breastfeeding gives baby enough immunity 
Had whooping cough as a child so have enough immunity 
Religious reasons 
Other reason 
 
51.3% (74) 
32.6% (47) 
12.5% (18) 
 
 4.1% (6) 
 0.6% (1) 
 0.6% (1) 
 0.6% (1) 
 0.6% (1) 
 
 
 254 
Content analysis was applied to the free text and was used to summarise recurring 255 
patterns across respondents in four emerging themes. 256 
3.6.1  Lack of information, awareness and professional encouragement 257 
The main reasons for declining the vaccine were the  lack of information and awareness 258 
of the vaccine combined with a lack of encouragement from familiar healthcare 259 
professionals. The vast majority (91.0% (182/200)) of women believed that their 260 
healthcare professional should provide them with more information about the 261 
recommended vaccinations during pregnancy. They requested that this information 262 
should be given in a timely manner supported by a meaningful discussion in order to 263 
make an informed decision about accepting or declining the vaccine within the optimal 264 
timeframe. Women who were undecided about accepting the vaccine also considered 265 
that it was important to be fully informed and that information should be more accessible. 266 
It was also apparent that women who sought advice wanted detailed information about 267 
the causes, symptoms, side-effects and significance of the disease in order to support 268 
their decision-making. 269 
Other important sources of information included discussions with relatives and friends, 270 
utilising media sources such as printed material and radio and actively seeking 271 
information on the internet.  Just 3.0% (6/200) of women indicated the public health 272 
campaign as their primary source of information. Of these, only one woman had received 273 
the vaccine. 274 
 275 
3.6.2  Natural is better 276 
Women thought that over-medication could be a hazard during pregnancy and that 277 
‘natural was better’. There was a firm belief that ‘nature would take care of things’. 278 
3.6.3  Perceived risks and safety concerns 279 
Some women worried about the side-effects of the vaccine on their unborn baby and to 280 
themselves. Others felt that there was insufficient evidence to support the use of the 281 
vaccine at this present time. Women’s perceptions of risk about vaccination both for 282 
themselves and their unborn baby influenced how they felt about accepting any vaccines 283 
during pregnancy. 284 
3.6.4  Not needed as low perceived susceptibility 285 
The vaccine was also considered unnecessary by some women who did not perceive that 286 
they were at sufficient risk of contracting  the disease. Women were associating their 287 
healthy lifestyle with being at ‘low risk’ of getting the disease. Furthermore, some women 288 
believed that breastfeeding provided all the immunity their baby would need to prevent 289 
them from developing the infection. 290 
3.7 Awareness of recommendations for vaccines in pregnancy in general 291 
In order to assess whether the attitude towards pertussis vaccine might also influence the 292 
uptake of other vaccines recommended in pregnancy, we included questions that related 293 
to both pertussis and influenza vaccine. Overall, 63.0% (126/200) of respondents were 294 
aware that the pertussis vaccine is recommended in pregnancy compared with 69.5% 295 
(139/200) aware of the maternal influenza vaccine programme (Fig.2)  296 
While 34.0% (68/200) of the respondents had been offered pertussis vaccination at their 297 
GP practice, only 24.0% (48/200) reported that they had discussed the issue with their 298 
GP. Some women had approached their GP and asked for the pertussis vaccine or for 299 
further information, nevertheless,  61.5% were not offered the vaccine and 4.5% could not 300 
remember. Of the 126 women who had been informed of the pertussis vaccination 301 
programme by their healthcare professional, 38.8% (49/126), nevertheless declined to 302 
take the pertussis vaccine.  303 
In contrast, 48% (96/200) of the respondents had been offered the influenza vaccine at 304 
their GP practice. Of the 139 women who were informed of the influenza vaccination 305 
programme by their healthcare professional, 50.3% (70/139) were vaccinated during 306 
pregnancy. 307 
3.8 Preferred sources of information 308 
When women were asked to report all known sources of information about the pertussis 309 
programme available to them, 16.6% (21/126)  indicated  the GP and midwife as the 310 
primary sources. Other sources of information included friends and the internet. Seventy 311 
four women(37.0%) were not aware of the vaccination programme. 312 
When asked about receiving information about vaccination programmes in the future, 313 
91.0% (182/200) of women said that it would be helpful to receive more information in a 314 
timely manner accompanied by a meaningful discussion and the opportunity to ask 315 
questions. Table 3 summarises the sources accessed and preferred sources of 316 
information for all future communications about vaccination in pregnancy.  317 
 318 
Table 3.  Sources of information accessed  by respondents 319 
 
Question: How were you informed about the whooping 
cough vaccination program? 
 
N=126 
 
 
Source of information: 
GP 
Midwife 
Antenatal clinic 
Other source (internet etc.) 
Media (newspaper, radio) 
Public health campaign 
Obstetrician 
 
 
24.0% (48) 
13.0% (26) 
10.0% (20) 
   9.0% (18) 
    4.0% (8)  
    2.5% (5) 
    0.5% (1) 
 
 
Question: How would you like to receive information about 
maternal vaccination in the future? (more than 1 answer 
allowed) 
  
 
Antenatal clinic 
GP 
Midwife 
Personal letter sent out in post 
Online website 
Leaflet or poster in clinic or surgery 
Text or email 
Maternity helpline 
Other 
Would prefer not to have any additional information 
Did not respond to question 
 
60.0% (120) 
59.0% (118) 
35.0% (70) 
22.0% (44) 
20.5% (41) 
19.0% (38) 
15.0% (30) 
1.0% (2) 
1.0% (2) 
5.0% (10) 
4.0% (8) 
 
 
 320 
 321 
4. DISCUSSION 322 
Despite an ongoing public health campaign to promote pertussis vaccination during 323 
pregnancy in the UK and new cases in infants in the community, uptake has varied 324 
considerably across the country and has remained comparatively low in London.  325 
We assessed the awareness and attitudes to pertussis vaccination in pregnancy using 326 
both quantitative and qualitative tools. Only 26.0% of women in our cohort had received 327 
the vaccine, considerably less than the 62.3% national coverage recently reported by 328 
PHE,[17] and fell short of the reported London coverage which ranged from 33.5% at 329 
worst to 53.3% in February 2013, [26]. PHE have  suggested that the published coverage 330 
data should be interpreted with caution due to inherent problems identified in data capture 331 
and reporting,[17]. Nonetheless,  our findings are a source of concern since they indicate 332 
a generally lower than average uptake of pertussis vaccination by pregnant women 333 
attending our busy, acute NHS Trust.  334 
It would appear that making decisions about accepting vaccine during pregnancy is a 335 
complex process and women will utilise their own beliefs, attitudes and values about 336 
vaccination in general when balancing perceived risks and benefits to themselves and 337 
their baby,[27]. However, consistent with similar studies our findings also highlight the 338 
importance of encouragement and recommendation by a familiar healthcare professional 339 
in this process,[27,28,29, 30].  340 
Despite recommendation from the UK Department of Health, awareness of the need for 341 
maternal vaccination was comparatively low at 63.0%, which, in itself represents a barrier 342 
to uptake. Lack  of awareness combined with a lack of encouragement by professionals 343 
were the main reasons given for not accepting the vaccine. Being informed was 344 
important, also noted in previous studies, [31,32] and being aware of the disease 345 
increases women’s probability of accepting the vaccine,[33]. Many women were sceptical 346 
of vaccine safety and efficacy despite published evidence,[34] and 91% wanted more 347 
information about vaccines in general. 348 
The main sources of information for pregnant women were GPs and midwives and yet 349 
women displayed misconceptions about the vaccine. This suggests that the information 350 
received was limited and difficult to interpret and only 24% of the women questioned 351 
reported a meaningful discussion with their GP. A study examining postpartum vaccine 352 
acceptance in a diverse sample of 815 Australian women also noted that access to 353 
information was significantly associated with uptake,[35].  354 
From the contrasting comments in this study -see supplementary document- it was 355 
obvious that women’s needs around obtaining and retaining information are very diverse. 356 
The experience reported here was one of disempowerment which ultimately impacted 357 
decision-making and maternal choice.  358 
Uptake varied across ethnic groups with only 7.1% of Black Caribbean women being 359 
vaccinated. This  finding is consistent with prior studies on racial disparity in vaccination 360 
practice which showed that black women are more likely to reject vaccination because 361 
they doubted the effectiveness, distrusted the healthcare system and feared they may 362 
become ill from the vaccine [36, 37, 38, 39].   This was an important finding given the 363 
significant number  of women with Black/Black British ethnicity booking for care at this 364 
Trust (18%). Understanding the target audience and engaging with key groups who 365 
influence women and parents in vaccination decision-making is important and might be 366 
influenced by ethnicity and possible disparities in access to PH materials or use of GP’s. 367 
Our questionnaire did not capture such details, but our subsequent focus group activities 368 
will be able to explore these issues in more depth.  369 
The latest enquiry into maternal deaths, Saving  Lives, Improving Mothers’ Care [40] 370 
reports that between 2009-2012, 357 women died during pregnancy or within six weeks 371 
of the end of their pregnancy. One in 11 of these women died from influenza and more 372 
than half of the influenza deaths could have been prevented by a flu vaccination. 373 
Compared with pertussis,  reported uptake of Influenza vaccine in our study was 9% 374 
higher. This difference may be attributed to greater awareness of the influenza vaccine 375 
during pregnancy and better availability at their GP  practice.  376 
Women were dissatisfied with the extent of information they received and resorted to 377 
researching information online as an alternative. There is little doubt that the development 378 
of new media such as the Internet and facilities such as NHS Direct have created easier 379 
access to ‘medical’ knowledge about pregnancy and childbirth, but, without professional 380 
help to explain the importance and relevance, misconstrued information may have caused 381 
women to reject the vaccination. This may be helped by emphasising the importance of 382 
maternal vaccination early in pregnancy at the first antenatal  appointment then following 383 
this up at each subsequent clinic attendance and support this discussion with the 384 
inclusion of the DH leaflets in the ‘booking pack’. Ideally, maternal vaccination should 385 
form part of the recommended information provided in the routine schedule of antenatal 386 
care and should be included in the National Institute for Health and Care Excellence 387 
(NICE) Antenatal Care Guidelines. 388 
A number of women expressed concerns about the safety and efficacy of the vaccine. 389 
Previous studies have shown that perception of harm to the baby or pregnant woman is 390 
directly related to vaccine refusal,[35,36,41,42,43]. An observational study of over 20000 391 
pregnant women who participated in the maternal vaccination programme in the UK, 392 
concluded that there were no safety concerns,[34]. The data also show that maternal 393 
immunisation with an acellular-pertussis-containing vaccine can provide 90% protection 394 
against infant disease,[16].  395 
Our results underline the critical role of healthcare professionals in advising and informing 396 
women in pregnancy. Only 24% of the women had engaged in a discussion with their GP 397 
about the vaccine. Other studies conducted during the H1N1 epidemic reported similar 398 
findings [31].  399 
In recognition of the need for accurate information which targets misconceptions we have 400 
recently developed a vaccination information telephone APP, and we are using a mobile 401 
vaccination information ‘hub’ which is ‘rolled out’ and displayed in the antenatal clinic area 402 
and manned by the research midwives. This allows women and professionals direct 403 
access to current information, is interactive and achieves better visibility than leaflets. 404 
 405 
With a growing body of evidence supporting the safety of the vaccine, weekly/monthly 406 
email shouts to healthcare professionals to update and increase awareness of current 407 
pertussis activity in the community would ensure staff are equipped to deal with queries 408 
efficiently.This type of information can be provided via text message and adapted for 409 
pregnant women and healthcare professionals alike, utilising the existing NHS text 410 
messaging service. 411 
Our study acknowledges some limitations. This was a cross-sectional study of only 200 412 
women at a single large NHS TRUST in London. However the sample was representative 413 
of the diverse population of women attending this Trust and our findings are likely to be 414 
applicable to many other settings caring for a similar population of women. 415 
We relied upon self-reported vaccine status and while this is recognised as a suitable 416 
alternative to medical record audit for determining vaccine uptake in adults, [44], there is 417 
potential for some reporting bias in our estimates of vaccine uptake.  418 
It could be argued that surveying women at 27 weeks gestation might have been too 419 
early. However, since the vaccine can be administered from 28 weeks onwards, women 420 
should ideally be made aware of the vaccine at least one week in advance and the 421 
average gestation in our study was 32 weeks. 422 
At the start of the DH pertussis campaign, pertussis-containing vaccine stocks were 423 
supplied to GP practices. With hindsight vaccine stocks may have been better placed in 424 
antenatal clinics where women could be informed about the vaccination programme and 425 
receive the vaccine without an additional visit to their GP practice. Both information and 426 
vaccines should be available at any point of contact with health services during 427 
pregnancy, with knowledgeable staff promoting their use. Comparative studies might be 428 
warranted to analyse where vaccination of pregnant women could be delivered with the 429 
highest success rates, and the opinion of pregnant women should be sought as part of 430 
this process. Some GP practices are likely to have much higher rates of uptake and 431 
pathways to success could be shared. 432 
In this campaign, communication of information used a top-down approach which, in this 433 
particular care setting was ineffective in delivering the key messages to staff in direct 434 
contact with pregnant women. In any future campaign it will be essential that PHE and DH 435 
engage directly with the staff delivering the care. In addition, although appropriate 436 
resources were developed to inform professionals and pregnant women, these are only 437 
provided on demand and not issued routinely to areas such as antenatal clinics.   438 
In summary, the main barriers to uptake of the maternal immunisation program were lack 439 
of awareness and the lack of accessible information about safety and rationale for the 440 
program. Healthcare professionals with GP’s and midwives in particular need to be more 441 
engaged in delivering these important messages to women in their care in an accessible 442 
and timely fashion.  Practically, a four-pronged approach should be employed, which  443 
delivers education for expecting parents, support for healthcare professionals with up to 444 
date knowledge, enhanced media coverage promoting the benefits of vaccination and 445 
increased understanding of the consequences of poor vaccine uptake for individuals and 446 
society. 447 
  448 
 449 
 450 
 451 
 452 
 453 
 454 
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